Viridian Therapeutics将同期股票和可转换票据价格上调3.5亿美元

2026-05-07 13:36

Viridian Therapeutics (VRDN) priced upsized concurrent public offerings totaling $350M in gross proceeds, including $225M of 1.75% convertible senior notes due 2032 and $125M of common stock.
The convertible notes will mature on May 15, 2032, unless earlier converted, redeemed, or repurchased. The initial conversion price is about $24.65 per share, representing a 45% premium to the common stock offering price.
Net proceeds are expected to be about $334.7M, and the company plans to use it to repay outstanding debt under its agreement with Hercules Capital, support market expansion studies for its thyroid eye disease franchise, advance earlier-stage pipeline programs, and for general corporate purposes.
The offerings are expected to close on May 11, 2026.
The stock price traded 1.25% lower on Wednesday during after-market hours.

More on Viridian Therapeutics